Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Aeterna Zentaris is a biotechnology business based in the US. Aeterna Zentaris shares (AEZS) are listed on the NASDAQ and all prices are listed in US Dollars.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $3.76 |
|---|---|
| 52-week range | $2.89 - $10.99 |
| 50-day moving average | $3.60 |
| 200-day moving average | $4.61 |
| Wall St. target price | $28.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.08 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.76 from 2023-02-01
| 1 week (2023-01-27) | 0.80% |
|---|---|
| 1 month (2023-01-03) | 16.77% |
| 3 months (2022-11-03) | -3.59% |
| 6 months (2022-08-03) | -25.10% |
| 1 year (2022-01-30) | N/A |
|---|---|
| 2 years (2021-02-03) | 295.79% |
| 3 years (2020-02-03) | 261.54% |
| 5 years (2018-02-02) | 79.90% |
| Revenue TTM | $4.1 million |
|---|---|
| Gross profit TTM | $5.2 million |
| Return on assets TTM | -12.09% |
| Return on equity TTM | -24.09% |
| Profit margin | 0% |
| Book value | $10.18 |
| Market capitalisation | $18.3 million |
TTM: trailing 12 months
We're not expecting Aeterna Zentaris to pay a dividend over the next 12 months.
Aeterna Zentaris's shares were split on a 1:25 basis on 20 July 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aeterna Zentaris shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Aeterna Zentaris shares which in turn could have impacted Aeterna Zentaris's share price.
Over the last 12 months, Aeterna Zentaris's shares have ranged in value from as little as $2.89 up to $10.9875. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeterna Zentaris's is 1.6637. This would suggest that Aeterna Zentaris's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aeterna Zentaris Inc. , a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.